Cullinan Therapeutics, Inc.

The Company expects that its cash, cash equivalents, and short-term investments of $ 334.5 million, and long-term investments and interest receivable of $ 21.4 million as of June 30, 2026, will be sufficient to fund its operating expenses and capital expenditure requirements through the next twelve months from the date of issuance of these consolidated financial statements.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(6) Stockholders' Equity Common Stock Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

No dividends have been declared through June 30, 2026.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Holders of preferred stock are entitled to receive when, as, and if dividends are declared and paid on the common stock, an equivalent dividend, calculated on an as-converted basis.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Shares of preferred stock are otherwise not entitled to dividends.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today provided an update on recent and anticipated business highlights and announced its financial results for the second quarter ended June 30, 2025.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

They are proven leaders with deep strategic and development expertise in immunology and oncology, respectively, and I believe their contributions will be invaluable as we continue to advance our programs.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

• CLN-619 (Anti-MICA/MICB monoclonal antibody) : NSCLC and multiple myeloma o Enrollment continues in the Phase 1 expansion cohorts in patients with NSCLC and the Phase 1 study in patients with relapsed/refractory multiple myeloma.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our preclinical and clinical developments plans and timelines for our product candidates, the clinical and therapeutic potential of our product candidates, the strategy of our product candidates, our research and development activities, our plans regarding future data presentations, our cash runway, and other statements that are not historical facts.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

SEC original ↗Cullinan Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 20 Item 1A.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled Risk Factors in our 2025 10-K and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Cullinan Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026